CLL Has Many Effective Drugs, And Costs Are Expected to Rise
Among the different forms of leukemia, chronic lymphocytic leukemia (CLL) is one of the most common in adults. The FDA has approved multiple treatments for the condition, making it a potential target of value-based contracts — assuming manufacturers would be amenable to such deals.
According to the American Cancer Society, about one-quarter of new leukemia cases are CLL, which is one of the more than 60 subtypes of non-Hodgkin lymphoma.
Related Posts

January 12
More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
READ MORE
January 12
New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati
READ MORE
January 12